Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2012 | original article | Ausgabe 17-18/2012

Wiener klinische Wochenschrift 17-18/2012

Effectiveness of the Austrian disease management programme “Therapie Aktiv” for type 2 diabetes regarding the improvement of metabolic control, risk profile and guideline adherence: 2 years of follow up

Zeitschrift:
Wiener klinische Wochenschrift > Ausgabe 17-18/2012
Autoren:
M.D., MPH10341_2012_166_Article_Validation Maria Flamm, Sigrid Panisch, Henrike Winkler, Tim Johansson, Raimund Weitgasser, Andreas C. Sönnichsen

Summary

Background

We evaluated the disease management programme (DMP) “Therapie Aktiv” for diabetes mellitus type 2 during the first year of implementation in a cluster-randomised controlled trial (RCT), which revealed an improvement of process quality, but only insignificant effects on HbA1c. To further analyse the effects of the DMP we followed up participants of the RCT for another year.

Methods

After completion of the RCT, the study was continued as an open observational trial. By patient’s choice, three groups were formed. Group 1 (DMP/DMP): interventions of the RCT (DMP), who remained in the DMP; group 2 (Control/DMP): controls of the RCT (usual care), who participated in the DMP during the second year; group 3 (Control/Control): controls of the RCT (usual care), who remained as controls. Primary outcome measure: HbA1c. Secondary outcome measures: BMI, lipids, blood pressure and measures of process quality.

Results

Only 801 of 1,489 RCT participants completed the study (53.8 %). Group 1: n = 355; group 2: n = 335; group 3: n = 111. After 2 years, pre-post-analysis revealed a significant reduction of HbA1c (0.37 %, p  < 0.001) in both DMP groups, and a reduction of only 0.03 % (p = 0.975) in the control group. However, the difference between the groups was not significant (p = 0.065). There was a significant improvement of process quality in the DMP groups compared with controls.

Conclusion

The DMP clearly enhances process quality. Furthermore, the DMP yields a reduction of HbA1c within groups after 2 years, but significance is lost in between-group analysis. We conclude that the DMP has only a minor effect on metabolic control.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 17-18/2012

Wiener klinische Wochenschrift 17-18/2012 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in Wien

Veranstaltungen

mitteilungen der gesellschaft

OeGIM-Homepage – Additivfächer